8 results about "Induction immunosuppression" patented technology

The invention discloses a composition capable of achieving double benefits of treatment and immune memory and application of the composition, and belongs to the technical field of biological medicine, and the pharmaceutical composition is composed of 5-carboxyl-8-hydroxyquinoline or pharmaceutically acceptable salt thereof and an anti-tumor drug nano preparation. Preferably, the doxorubicin liposome is composed of 5-carboxyl-8-hydroxyquinoline or a pharmaceutically acceptable salt thereof and a sialic acid functional group modified doxorubicin liposome. The composition can promote antigen presenting cell functions, enhance T cell activity, strengthen T cell memory formation, induce deep remodeling of an immunosuppression microenvironment and training immunity of a congenital immune system, generate strong immune memory, realize comprehensive killing of homologous or heterologous tumors, and has a good application prospect. The recurrence of primary tumors, the generation of secondary primary cancers and the attack of other newborn cancers are prevented.

The invention discloses a mechanism for promoting colorectal cancer through macrophage polarization and an IL-17 (interleukin-17) pathway by Streptococcus gallyticus streptococcus metabolite and application of the Streptococcus gallyticus streptococcus metabolite, and relates to the technical field of microorganism-tumor immunoregulation. According to the invention, specific metabolites, namely inosine-5 '-monophosphate (IMP), methionine, uridine and creatine, in a Streptococcus gallyticus supernatant promote CRC (cyclic redundancy check) through the following two paths: M2 polarization of macrophages: TAM infiltration of tumor-related macrophages is remarkably increased, an immunosuppressive microenvironment is induced, and tumor growth is promoted; and IL-17 signal channel activation: RNA-seq shows that the IL-17 channel is the most significant enrichment channel, the expression of IL-17F and IL-22 is specifically up-regulated, and inflammation and tumor progression are promoted. The invention reveals that the Sg metabolite is a key driving factor of CRC instead of bacteria for the first time, reveals a mechanism that the Sg metabolite activates and promotes colorectal cancer through macrophage M2 polarization and IL-17 pathway, provides an application value of the Sg metabolite in CRC diagnostic marker screening and targeted therapeutic drug development, and provides a new idea for CRC diagnosis and treatment.

The invention provides an inhalable T cell activation nano platform suitable for lung cancer immunotherapy and a preparation method and application thereof. The nano-platform comprises a MoS2-statin nano-platform formed by loading IL-2 and anti-PD-1 protein on a MoS2 nano-sheet, and the platform realizes the treatment effect through the following modes: by accurately controlling the particle size of nano-particles, the nano-particles can be efficiently deposited in a lung tumor area, the local drug concentration is remarkably improved, the whole body exposure is reduced, and the side effect of intravenous administration is avoided; the proliferation and immune response of CD8 + T cells are enhanced through the synergistic effect of IL-2, the drug resistance of PD-1 is reduced, and the treatment effect of the immune checkpoint inhibitor is improved in combination with the immunomodulatory function of MoS2; copper death of immunosuppressive Treg cells is induced through the MoS2 nano platform, the immunosuppressive cells in a tumor microenvironment are removed, the immune drug resistance bottleneck in immunotherapy is broken through, and an innovative treatment means with high targeting, remarkable curative effect and small side effect is provided for lung cancer patients.

The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and / or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.

Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and / or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.

The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts, stereoisomers, diastereoisomers, enantiomers, polymorphs, racemic mixtures, solvates or isomers and mixtures thereof. The invention also relates to a process for the stereoselective preparation of such compounds. The compounds of formula (I) are useful as medicaments, in particular for inhibiting crown protein 1 expression in the induction of immunosuppression or in the treatment and / or prevention of diseases or disorders selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases and lymphoproliferative disorders. The present invention also relates to a vector comprising a crown protein 1 promoter element wherein the crown protein 1 promoter element starts directly upstream of the transcription start site (TSS) of the crown protein 1 gene and spans a sequence segment of at least about 700 bp in the genome in the vertebrate genome. The invention also relates to a method for identifying immunomodulatory compounds that alter the activity of the crown protein 1 promoter using said vector. The invention also relates to BRD3 as an upstream target responsible for driving crown protein-1 expression and activity in immune cells, and to compounds that selectively target the bromodomain of BRD3 and thereby deplete crown protein 1 levels, in particular compounds of formula (I). # imgabs0 #

To provide cells that are competitive against cancer cells without starving or becoming exhausted even in glucose-depleted environments. To provide cells that are effective in metabolic (e.g., low glucose, high lactate, high fatty acid) and immunological tumor environments (e.g., chemokine profiles that induce immunosuppressive immune cells, expression of checkpoint molecules, and infiltration of suppressor cells that negatively regulate anti-tumor immune responses, such as inhibitory cytokines and Treg cells) in which normal T cells or conventional genetically modified cells are inhibited from infiltrating and, even if they infiltrate, are unable to exert long-term effector function due to starvation or exhaustion. [Solution] T cells with effector function, which have been modified to express Foxp3 (including mutant and partially deleted forms) and / or have enhanced Foxp3 expression.

The present invention relates to immunosuppressive compounds that deplete coronin 1 levels, in particular to coronin 1 promoter inhibitors. Accordingly, the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, diastereoisomer, enantiomer, polymorph, racemic mixture, or solvate thereof. The compound of formula (I) can be used as a medicament, in particular for inhibiting coronin 1 expression in the induction of immunosuppression or in the treatment and / or prevention of a disease or disorder selected from the group consisting of transplant rejection, autoimmune diseases, inflammatory diseases, infectious diseases, and lymphoproliferative disorders. The present invention further relates to a pharmaceutical composition comprising the compound of the present invention and a pharmaceutically acceptable carrier.